Newsgroup: it.economia.borsa
Titolo: report cell

      CTI Reports 2004 Quarterly and Year End Results
      XYOTAX(TM) STELLAR 3 Pivotal Trial Results Expected in the First Half 
of March Provide Potential for 2005 to Be Transforming Year for CTI
      SEATTLE, Feb 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- Cell 
Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) reported financial 
results for the quarter and year ended December 31, 2004. Total revenues for 
the quarter were $8.1 million compared to $7.2 million in the fourth quarter 
of 2003. CTI reported a net loss for the quarter of $43.5 million ($0.72 per 
share) compared to net loss of $36.7 million ($1.09 per share) for the same 
period in 2003.
      Total revenues for the year ended December 31, 2004, rose to $29.6 
million compared to $24.8 million in 2003. For the year, CTI posted a net 
loss of $252.3 million, including $87.4 million related to an in-process 
research and development charge as a result of the acquisition of 
Novuspharma S.p.A., compared to a net loss of $130.0 million in 2003. The 
Company ended the year with cash, cash equivalents, securities 
available-for-sale and interest receivable of approximately $116.0 million. 
Sales of TRISENOX(R) for the quarter were $6.4 million compared to $6.6 
million in the same period in 2003. The Company had previously guided for 
lower sales as a result of the launch of a competing product and foresees 
2005 net sales of TRISENOX of approximately $29 million as the commercial 
team prepares for the potential launch of XYOTAX.
      "We made significant progress in 2004 across all aspects of our 
business and are now hoping to harvest the rewards of those efforts as we 
prepare to analyze the results of three phase III trials for XYOTAX in lung 
cancer for the potential submission of a new drug application (NDA) later 
this year," noted James A Bianco, M.D., President and CEO of CTI. "With 
everyone focused on XYOTAX, it is easy to forget that we also have the 
potential for an interim analysis for our pivotal trial of pixantrone in 
aggressive lymphoma at the end of this year, which could lead to an NDA 
submission in 2006. With a robust pipeline of novel oncology products and 
upcoming pivotal milestones, we believe this may be a transforming year for 
CTI."
2004 Highlights
     * CTI completed its merger with Italian biopharmaceutical company
       Novuspharma, S.p.A. improving CTI's European presence, strengthening
       the balance sheet, adding development expertise, and adding a phase 
III
       product candidate, pixantrone, to the product pipeline.
     * CTI expanded its European commercial operations by hiring trained
       European sales personnel. The expanded commercial presence provides 
the
       critical mass needed to expand sales of TRISENOX in Europe.
     * CTI partnered with the Gynecologic Oncology Group (GOG) on a phase 
III
       clinical trial of XYOTAX in patients with ovarian cancer by signing a
       clinical trials agreement for the GOG to sponsor and conduct the 
study,
       agreeing on the study design for XYOTAX pivotal trial in ovarian
       cancer, and supporting the GOG in submitting an Investigational New
       Drug (IND) application along with a request for a Special Protocol
       Assessment (SPA).
     * CTI initiated a pivotal trial of pixantrone in aggressive 
non-Hodgkin's
       lymphoma, with acceptance of trial parameters under the FDA's special
       protocol assessment (SPA) process, and received fast track 
designation
       for pixantrone for the treatment of relapsed, aggressive NHL.
     * CTI initiated two phase I/II clinical trials of CT-2106: one in
       combination with 5-FU/leucovorin in patients with metastatic 
colorectal
       cancer and a single agent trial in ovarian cancer.
     * The U.S. Patent and Trademark office issued a patent for TRISENOX,
       extending marketing exclusivity from 2007 to 2018.
     * CTI completed enrollment in XYOTAX STELLAR 2 and 4 phase III clinical
       trials; the largest PS2 and second-line clinical studies ever 
conducted
       in non-small cell lung cancer.
     * CTI raised approximately $64 million through a public and a 
registered
       direct offering
     * CTI entered into a financing and services agreement with PharmaBio
       Development, the strategic partnering group of Quintiles 
Transnational,
       Corp. for royalties and clinical services based on a percentage of 
net
       sales of TRISENOX.
    About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to 
developing an integrated portfolio of oncology products aimed at making 
cancer more treatable. For additional information, please visit 
www.cticseattle.com
.
      This press release includes forward-looking statements that involve a 
number of risks and uncertainties, the outcome of which could materially 
and/or adversely affect actual future results. Specifically, the forward- 
looking statements contained in this press release include statements about 
future financial and operating results and risks and uncertainties that 
could affect the development of CTI's products under development, including 
TRISENOX, XYOTAX, and pixantrone. These risks include, but are not limited 
to, preclinical clinical, and sales and marketing developments in the 
biopharmaceutical industry in general and in particular including, without 
limitation, the enrollment and completion of planned and ongoing clinical 
trials, the potential failure to meet TRISENOX revenue goals, the potential 
failure of TRISENOX to continue to be safe and effective for cancer 
patients, the potential failure of XYOTAX to prove safe and effective for 
non-small cell lung and ovarian cancers, the potential failure of pixantrone 
to prove safe and effective for relapsed aggressive non-Hodgkin's lymphoma, 
determinations by regulatory, patent and administrative governmental 
authorities, competitive factors, technological developments, costs of 
developing, producing and selling TRISENOX, and CTI's products under 
development; and the risk factors listed or described from time to time in 
the Company's filings with the Securities and Exchange Commission including, 
without limitation, the Company's most recent filings on Forms 10-K, 8-K, 
and 10-Q.
Cell Therapeutics, Inc.
               Condensed Consolidated Statements of Operations
                   (In thousands, except per share amounts)
                                      Three Months Ended       Year Ended
                                         December 31,         December 31,
                                        2004      2003      2004       2003
    Revenues:
       Product sales                   $6,402    $6,604    $26,626 
$22,105
       License and contract revenue     1,728       612      2,968 
2,660
       Total revenues                   8,130     7,216     29,594 
24,765
    Operating expenses:
       Cost of product sold               246       221      1,104 
840
       Research and development        27,840    24,411    101,127 
89,534
       Selling, general and
        administrative                 20,108    16,542     78,522 
55,641
       Acquired in-process research
        and development                  (745)       --  
75         --
       Amortization of purchased
        intangibles                       578       334      2,294 
1,335
       Total operating expenses        48,027    41,508    270,422 
147,350
    Loss from operations              (39,897)  (34,292)  (240,828) 
(122,585)
    Other income (expense):
       Investment and other income        381       384      1,636 
1,880
       Interest expense                (2,840)   (2,759)   (10,988) 
(9,326)
       Foreign exchange loss           (1,181)       --  
118)        --
    Net loss                         $(43,537) $(36,667) $(252,298) 
$(130,031)
    Basic and diluted net loss per
     share                             $(0.72)   $(1.09)    $(4.67) 
$(3.89)
    Shares used in calculation of basic
     and diluted net loss per share    60,701    33,774     54,052 
33,418
    Balance Sheet Data:                          (amounts in thousands)
                                                 December 31,     December 
31,
                                                     2004              2003
    Cash, cash equivalents, securities available-
     for-sale and interest receivable              $116,020 
$92,838
    Working capital                                  93,813 
71,898
    Total assets                                    184,996 
146,090
    Convertible debt                                190,099 
190,099
    Accumulated deficit                            (722,784) 
(470,486)
    Shareholders' deficit                           (70,708) 
(82,542)
SOURCE Cell Therapeutics, Inc.
Investors, Leah Grant, 
+1-206-282-7100
, or fax, 
+1-206-272-4010
, or
inv...@ctiseattle.com
, or Media, Susan Callahan, 
+1-206-272-4472
, or fax,
+1-206-272-4010
, or 
me...@ctiseattle.com
, both of Cell Therapeutics, Inc.
http://www.prnewswire.com

 EPS -0,72 contro un atteso -0,5/-0,59
risultati brutti (peggio delle previsioni, che erano già negative) , come 
previsto da Syber adesso la butteranno giu' fino ai supporti perf far uscire 
molti e rastrellare alla grande, in attesa che tra pochi giorni escano 
risultati ottimi sullo xyotax che faranno volare il titolo, ma prima dovrà 
ripassare per i 9 dollari.
cmq è decisivo quello che diranno nella conference che comincia alle 14,30 e 
dall'andamento dell'azione in usa dopo l'aperturta delle 15,30 si capirà 
quello che dicono;
io sono fuori e ci resto fino a stasera domani: voglio decidere a bocce 
ferme

Forse oggi in USA potrebbero strapazzarla davvero.Attendo le 15,30, potrebbe
anche essere un'occasione unica x entrare

 potrebbe anche essere un'occasione unica x entrare
Il pre-market sembra reagire positivamnte (ma vedo solo i dati ritardati di 
Yahoo...) con +1.08%...
Che sia una scontata Bull Trap? 


Bravo, hai capito tutto in una parola. I risultati non contano. Cell ha 
sempre battuto in negativo le previsioni sui bilanci, in Usa è scontato e lo 
sanno. 

 scontato e lo sanno.
Che strano, perň...
Se avessimo ragione ... mi aspetterei delle vendite consitenti anche in 
Italia in attesa del crollo negli USA... ma non le vedo. Anzi sembrano tutti 
titubanti e il titolo si muove - in Italia - con pochissimi volumi anche se 
in ribasso.
Istruttivo.... 

 di Yahoo...) con +1.08%...
Fate attenzione, io sono stato tentato di vendere 20 minuti fa dopo aver 
letto il NG ma poi ho pensato che negli USA il mercato premia molto le 
prospettive di crescita 

 ha scritto nel messaggio 
news:39FUd.72161$2h5....@tornado.fastwebnet.it...

LOL!
Il mercato italiano č quello dove i Romiti con 50 milioni controllano 
un'azienda che ne valeva piů di 1000, alla fine, forse per invidia, hanno 
fatto in modo che valesse 500 milioni :-D 

 prospettive di crescita
In questi casi si deve seguire l'istinto. I risultati potrebbero essere una 
scusa per buttare giù il titolo, ma dal punto di vista logico in usa sono 
già scontati.
Vorranno fare una bulltrap come dice Bart o prenderanno tutti in 
contropiede? 


E' un ragionamento un po' teorico... ma mi aspetterei che le cosiddette 
"mani forti" si siano già posizionate in Italia in attesa dell'andamento del 
titolo in USA che, sicuramente, conoscono già a - almeno - lo prevedono. Ma 
non ho visto  tutti questi movimenti e continuo a non vederli... Il problema 
è che c'e' in ballo questo nuovo preparato anti-cancro e se sapessero già 
dei risultati positivi, credo che questo limiti un po' le loro "trappole" 

naturalmente l'at non vi frega 

 naturalmente l'at non vi frega
Miiiii..... ma hai l'artrosi alle mani? Sei paralitico e devi scrivere con 
la bocca? Hai la diarrea e non puoi stare più di 5 secondi alla tastiera? 
Sei minorenne e non hai il permesso di toccare il PC di papa?
Niente di tutto questo?
E allora perchè ca**o non ti fo**i a essere più chiaro o ci liberi di questi 
insulsi commenti. 

 ha scritto nel messaggio
news:bGFUd.72273$2h5....@tornado.fastwebnet.it...


tu sei un cialtrone, sto linguaggio usalo con i tuoi omologhi !